JP2000510692A5 - - Google Patents

Download PDF

Info

Publication number
JP2000510692A5
JP2000510692A5 JP1997539625A JP53962597A JP2000510692A5 JP 2000510692 A5 JP2000510692 A5 JP 2000510692A5 JP 1997539625 A JP1997539625 A JP 1997539625A JP 53962597 A JP53962597 A JP 53962597A JP 2000510692 A5 JP2000510692 A5 JP 2000510692A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP1997539625A
Other languages
English (en)
Japanese (ja)
Other versions
JP2000510692A (ja
Filing date
Publication date
Priority claimed from GBGB9609405.7A external-priority patent/GB9609405D0/en
Priority claimed from GBGB9703103.3A external-priority patent/GB9703103D0/en
Application filed filed Critical
Priority claimed from PCT/GB1997/001165 external-priority patent/WO1997042329A1/en
Publication of JP2000510692A publication Critical patent/JP2000510692A/ja
Publication of JP2000510692A5 publication Critical patent/JP2000510692A5/ja
Pending legal-status Critical Current

Links

JP09539625A 1996-05-04 1997-04-29 Ceaに対するモノクローナル抗体、その抗体を含む結合体、およびadeptシステムにおけるそれらの治療的使用 Pending JP2000510692A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB9609405.7A GB9609405D0 (en) 1996-05-04 1996-05-04 Protein
GB9609405.7 1996-05-04
GB9703103.3 1997-02-14
GBGB9703103.3A GB9703103D0 (en) 1997-02-14 1997-02-14 Protein
PCT/GB1997/001165 WO1997042329A1 (en) 1996-05-04 1997-04-29 Monoclonal antibody to cea, conjugates comprising said antibody, and their therapeutic use in an adept system

Publications (2)

Publication Number Publication Date
JP2000510692A JP2000510692A (ja) 2000-08-22
JP2000510692A5 true JP2000510692A5 (OSRAM) 2004-12-09

Family

ID=26309272

Family Applications (1)

Application Number Title Priority Date Filing Date
JP09539625A Pending JP2000510692A (ja) 1996-05-04 1997-04-29 Ceaに対するモノクローナル抗体、その抗体を含む結合体、およびadeptシステムにおけるそれらの治療的使用

Country Status (19)

Country Link
US (2) US6277599B1 (OSRAM)
EP (1) EP0896626B1 (OSRAM)
JP (1) JP2000510692A (OSRAM)
CN (1) CN1217750A (OSRAM)
AT (1) ATE350478T1 (OSRAM)
AU (1) AU719513B2 (OSRAM)
BR (1) BR9708910A (OSRAM)
CA (1) CA2250579A1 (OSRAM)
CZ (1) CZ353698A3 (OSRAM)
DE (1) DE69737188T2 (OSRAM)
ES (1) ES2279539T3 (OSRAM)
HU (1) HUP9901562A3 (OSRAM)
IL (1) IL126772A0 (OSRAM)
NO (1) NO985120L (OSRAM)
NZ (1) NZ331978A (OSRAM)
PL (1) PL329871A1 (OSRAM)
SK (1) SK150298A3 (OSRAM)
TR (1) TR199802227T2 (OSRAM)
WO (1) WO1997042329A1 (OSRAM)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK150298A3 (en) * 1996-05-04 1999-04-13 Zeneca Ltd Monoclonal antibody to cea, conjugates comprising said antibody, and their therapeutic use in an adept system
WO1998035988A1 (en) * 1997-02-14 1998-08-20 Zeneca Limited Proteins
GB9709421D0 (en) * 1997-05-10 1997-07-02 Zeneca Ltd Chemical compounds
WO2001036486A2 (en) * 1999-11-18 2001-05-25 Oxford Biomedica (Uk) Limited Scfv antibodies against disease associated molecules
CA2321947A1 (en) * 1998-02-25 1999-09-02 The Dow Chemical Company High affinity humanized anti-cea monoclonal antibodies
EP1131428A2 (en) * 1998-11-19 2001-09-12 Incyte Pharmaceuticals, Inc. Immunoglobulin superfamily proteins
JP2002533072A (ja) * 1998-12-21 2002-10-08 イーライ・リリー・アンド・カンパニー β−リポトロピンおよび他のペプチドの組換え合成
GB2371803A (en) * 1999-11-18 2002-08-07 Oxford Biomedica Ltd Antibodies
AU2001262216A1 (en) * 2000-04-22 2001-11-07 Stefan Barth Apoptotic agents
GB0210783D0 (en) * 2002-05-10 2002-06-19 Polonelli Luciano Anti-microbial polypeptides
KR100604037B1 (ko) * 2002-08-02 2006-07-24 주식회사유한양행 항체 경쇄 카파 발현벡터
US20050008618A1 (en) * 2003-02-27 2005-01-13 Howard Kaufman Composition for delivering an agent to a target cell and uses thereof
JP2006520610A (ja) * 2003-03-04 2006-09-14 アレクシオン ファーマシューティカルズ, インコーポレイテッド ハイブリッド不変領域を産生するのに用いるベクター
CN1795010A (zh) * 2003-04-23 2006-06-28 梅达雷克斯公司 针对α干扰素受体-1(IFNAR-1)的人源化抗体
EP1691763A4 (en) * 2003-12-12 2008-03-12 Genencor Int MOLECULES CAB
AU2005214331B2 (en) 2004-02-12 2011-09-15 Eisai, Inc. Monoclonal antibodies that specifically bind to folate receptor alpha
JP4699450B2 (ja) * 2004-04-15 2011-06-08 ジェネンコー・インターナショナル・インク Cab分子、ceaを対象とするadept構築
EP2366717A3 (en) 2004-10-29 2011-12-14 University of Southern California Combination Cancer Immunotherapy with Co-Stimulatory Molecules
AU2006223301B2 (en) 2005-03-10 2010-11-04 Eisai, Inc. Anti-mesothelin antibodies
EP2172487A1 (en) 2005-04-22 2010-04-07 Morphotek Inc. Antibodies with Immune Effector Activity that Internalize in Folate Receptor Alpha-Positive Cells
WO2007036745A2 (en) 2005-09-30 2007-04-05 Medimmune Limited Interleukin-13 antibody composition
US8993295B2 (en) 2006-07-20 2015-03-31 The General Hospital Corporation Methods, compositions, and kits for the selective activation of protoxins through combinatorial targeting
US8043830B2 (en) * 2008-02-01 2011-10-25 The Regents Of The University Of California Biotin-ligase system for secretion of biotinylated protein
CN101607985B (zh) * 2008-12-24 2013-03-27 中国科学院生物物理研究所 抗人cea的单克隆抗体,包含其的组合物,及其用途
CN101704892B (zh) * 2009-12-09 2014-02-12 中国人民解放军军事医学科学院生物工程研究所 一种抗uPAR人源化抗体及其编码基因与应用
UY33202A (es) * 2010-01-28 2011-08-31 Glaxo Group Ltd Proteínas de unión a cd127
CN107936121B (zh) 2011-05-16 2022-01-14 埃泰美德(香港)有限公司 多特异性fab融合蛋白及其使用方法
KR102096224B1 (ko) 2011-10-28 2020-04-03 테바 파마슈티컬즈 오스트레일리아 피티와이 엘티디 폴리펩티드 구축물 및 이의 용도
CN102526707B (zh) * 2012-01-13 2015-04-22 成都博发生物技术有限公司 共刺激因子及融合蛋白的新用途
RU2493166C1 (ru) * 2012-04-09 2013-09-20 Общество с ограниченной ответственностью "Технофарма" Наноантитело, специфически связывающее белок сеа, способ его использования для детекции этого белка
CN102838676A (zh) * 2012-09-26 2012-12-26 李彬 一种癌胚抗原单抗及包含该抗体的芯片以及应用
WO2014057074A1 (en) 2012-10-12 2014-04-17 Spirogen Sàrl Pyrrolobenzodiazepines and conjugates thereof
AU2014230735B2 (en) 2013-03-13 2018-03-15 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
US11117975B2 (en) 2013-04-29 2021-09-14 Teva Pharmaceuticals Australia Pty Ltd Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
EP2992013B1 (en) 2013-04-29 2019-12-04 Teva Pharmaceuticals Australia Pty Ltd Anti-cd38 antibodies and fusions to attenuated interferon alpha-2b
UA119352C2 (uk) 2014-05-01 2019-06-10 Тева Фармасьютикалз Острейліа Пті Лтд Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину
US10188746B2 (en) 2014-09-10 2019-01-29 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
UA125637C2 (uk) 2014-10-29 2022-05-11 Тева Фармасьютікалз Острейліа Пті Лтд ЗЛИТИЙ ПОЛІПЕПТИД ІНТЕРФЕРОНУ <font face="Symbol">a2</font>b
US10870701B2 (en) 2016-03-15 2020-12-22 Generon (Shanghai) Corporation Ltd. Multispecific fab fusion proteins and use thereof
US11618784B2 (en) 2016-07-19 2023-04-04 Teva Pharmaceuticals Australia Pty Ltd. Anti-CD47 combination therapy
US20200023072A1 (en) 2016-10-11 2020-01-23 Medimmune Limited Antibody-drug conjugates with immune-mediated therapy agents
CN111499750B (zh) * 2016-12-04 2022-02-08 深圳市国创纳米抗体技术有限公司 一种抗癌胚抗原的高中和活性纳米抗体及其应用
BR112020023846A2 (pt) 2018-05-23 2021-04-13 Adc Therapeutics Sa Adjuvante molecular
EP3847196A4 (en) 2018-09-07 2023-01-04 ITabMed (HK) Limited BISPECIFIC ANTIGEN BINDING PROTEINS AND USES THEREOF
WO2021041725A1 (en) * 2019-08-27 2021-03-04 The Trustees Of The Univeristy Of Pennsylvania SYNTHETIC CARS TO TREAT IL13Rα2 POSITIVE HUMAN AND CANINE TUMORS
WO2022079211A1 (en) 2020-10-16 2022-04-21 Adc Therapeutics Sa Glycoconjugates
CN115850483B (zh) * 2020-10-21 2025-09-19 北京纽安博生物技术有限公司 抗CEACAM6单域抗体、人源化单域抗体及其Fc融合蛋白和应用
GB202102396D0 (en) 2021-02-19 2021-04-07 Adc Therapeutics Sa Molecular adjuvant
WO2022078524A2 (en) 2021-11-03 2022-04-21 Hangzhou Dac Biotech Co., Ltd. Specific conjugation of an antibody

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8809616D0 (en) 1988-04-22 1988-05-25 Cancer Res Campaign Tech Further improvements relating to drug delivery systems
GB9014932D0 (en) * 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
JPH08509612A (ja) 1993-04-26 1996-10-15 ジェンファーム インターナショナル インコーポレイテッド 異種抗体を産生することができるトランスジェニック非ヒト動物
GB9324807D0 (en) 1993-12-03 1994-01-19 Cancer Res Campaign Tech Tumour antibody
US5874540A (en) 1994-10-05 1999-02-23 Immunomedics, Inc. CDR-grafted type III anti-CEA humanized mouse monoclonal antibodies
SK150298A3 (en) * 1996-05-04 1999-04-13 Zeneca Ltd Monoclonal antibody to cea, conjugates comprising said antibody, and their therapeutic use in an adept system

Similar Documents

Publication Publication Date Title
JP2000502280A5 (OSRAM)
JP2002515149A5 (OSRAM)
JP2000501599A5 (OSRAM)
JP2001509322A5 (OSRAM)
JP2000502472A5 (OSRAM)
JP2000501825A5 (OSRAM)
JP2000515132A5 (OSRAM)
JP2000510692A5 (OSRAM)
JP2000502485A5 (OSRAM)
JP2000502425A5 (OSRAM)
JP2000515107A5 (OSRAM)
JP2000502568A5 (OSRAM)
JP2000510848A5 (OSRAM)
JP2000502570A5 (OSRAM)
JP2000501876A5 (OSRAM)
JP2000511955A5 (OSRAM)
JP2000502316A5 (OSRAM)
JP2000502714A5 (OSRAM)
JP2000511972A5 (OSRAM)
JP2000501569A5 (OSRAM)
JP2000510398A5 (OSRAM)
JP2000502479A5 (OSRAM)
JP2001503957A5 (OSRAM)
JP2001523296A5 (OSRAM)
JP2000502497A5 (OSRAM)